ADAR1 Capital Expands Biotech Portfolio Across Five Stocks

23 sourcesUpdated Aug 26, 2026

ADAR1 Capital Management LLC disclosed new positions in five biotech and medical tech companies during the second quarter, according to Holdings Channel reports. It bought 38,955 shares of ACADIA Pharmaceuticals Inc. (about $986,000). It opened a position in Adagio Medical Holdings, acquiring 1,205,447 shares valued at roughly $785,000. The firm also added 272,745 shares of Larimar Therapeutics, Inc. worth about $832,000. Artiva Biotherapeutics, Inc. saw ADAR1 acquire 118,624 shares valued around $1,151,000, while Corvus Pharmaceuticals, Inc. recorded a new stake of 117,101 shares valued about $1,749,000. These moves illustrate ADAR1's active deployment across multiple healthcare names, part of a broader pattern of institutional activity in these stocks.

In this story:Adenosine deaminase, RNA specific

Where do you stand?

Adenosine deaminase, RNA specific

Q2 2026 institutional 13F filings reveal fresh stock stakesstory 9 of 9 · since Aug 23, 2026

Aug 23, 2026Aug 26, 2026

Aug 26, 2026ADAR1 Capital Management discloses new Q2 stakes in five biopharma companies, including ACADIA Pharmaceuticals and Larimar Therapeutics, worth up to about $1.9 million each.
Aug 24, 2026Osmosis Investment Management UK discloses new Q2 stakes worth over $22 million across Ecolab, Bank of New York Mellon, Jacobs Solutions and Pacific Gas & Electric.
Aug 24, 2026Pinnacle Holdings discloses new Q2 stakes in First United, JetBlue Airways, Crescent Energy, Deutsche Bank and Talos Energy worth between $439,000 and $2.6 million.